From: Mineralocorticoid receptor antagonists in dialysis patients
Author | Number of patients | Administration period | Study duration | Results | Change of plasma potassium |
---|---|---|---|---|---|
Hausmann et al. [57] | One PD patient | Spironolactone 25Â mg/day | 10Â months | LVEF increased. | Potassium level was below 5.1 at pretreatment and below 5.5Â mEq/l after spironolactone treatment. |
Taheri et al. [58] | 9 PD patients with heart failure | Spironolactone 25 mg every other day | 6 months | LVEF increased. | There was no significantly difference between spironolactone and placebo groups (P > 0.05). One patient in the spironolactone group developed hyperkalemia (K = 5.70 mEq/l). |
Ito et al. [60] | 78 PD patients | Spironolactone 25 mg/day | 2 years | LV mass index and LVEF improved. | Potassium levels were significantly higher in the spironolactone group after 6 and 12 months (P < 0.05). Two patients in the spironolactone group developed hyperkalemia (K = 6.0 mEq/l), and one patient (K = 6.1 mEq/l) in the control group. |
Yongsiri et al. [59] | 24 PD patients with hypokalemia | Spironolactone 25 mg/day | 4 weeks |  | Potassium levels 4.23 ± 0.64 at base line and 3.90 ± 0.59 mEq/l after 4 weeks (P = 0.077). One patient in the spironolactone group developed hyperkalemia (K = 5.6 mEq/l). |
Yelken et al. [72] | 23 PD patients | Spironolactone 25 mg/day | 6 months | Dialysate CA125 increased. Residual GFR declined. | Potassium level 4.3 ± 0.5 at baseline and 4.4 ± 0.6 mEq/l after 6 months (P = 0.488). |
Vazquez-Rangel et al. [73] | 9 PD patients | Spironolactone 25 mg/day | 6 months | CD20 and collagen IV levels in peritoneal biopsy specimens decreased. | Potassium levels 4.8 ± 0.4 in the spironolactone group and 4.4 ± 0.5 mEq/l in the control group (P = 0.2). |